Some principles of endocrine therapy for breast cancer

1. Endocrine therapy and chemotherapy should not be used together in the same period of time. Endocrine therapy in the past have always thought that was "effective inaccurate, non-essential auxiliary treatment", most doctors can not alone endocrine therapy, endocrine therapy has been confirmed can be obtained similar effects with chemotherapy, alone can not only play them in Different time period, the biggest role, but also beneficial to observe the efficacy of screening of effective treatments. If endocrine therapy 1-2 months after the progress of the disease, should be bold and disable the endocrine therapy, chemotherapy or other use of new endocrine drugs.

2. As long as possible endocrine treatment, during treatment do not have to blindly pursue CR + PR rate, but also should pay attention to CR + PR + ' 6 months of the clinical effectiveness of SD, as long as no progress disease (PD), it should always insist on endocrine treatment, best to continue medication 3-5 years.

3. As soon as possible endocrine therapy as first-line treatment, has never Letrozole (Teflon) and see the results of clinical studies, preoperative neoadjuvant therapy response rate was 50% of first-line treatment to save 30%, second-line rescue for about 20%. In addition, despite the first-line treatment and second-line treatment in an efficient, significant difference, still can not give up late second-line treatment of patients.

4. Endocrine cross-resistance among the very few, if a drug-resistant can choose another endocrine drugs, in the past once the new re-use and effective in patients with endocrine drugs may also be effective.

5. Pay attention to Her-2 gene on the effects of endocrine therapy resistance.

6. Do not give up the treatment of patients with bone metastases. Lesions of bone metastasis is unmeasured, but it remains to assess the lesion, letrozole first-line treatment of bone metastasis rate was 22%, second-line treatment is still up to 15-16%, the progress of first-line treatment of lesions in the median time to 9 -7 months. 1-2 months after the medication as long as the symptoms improved, X-ray showed osteolytic destruction zones at a small calcification should understand that the PR, continue to adhere to endocrine therapy.